Tirofiban administration during primary PCI can trigger acute, extensive thrombocytopenia within hours, requiring prompt recognition and management.
Acute tirofiban-related thrombocytopenia in PCI demands rapid recognition and management; case-level evidence leaves incidence and prevention strategies open.
Tirofiban, a specific glycoprotein IIb/IIIa inhibitor, may cause extensive thrombocytopenia with an incidence of 0.2% to 0.5%. We report the case of a 50-year-old man who developed thrombocytopenia after tirofiban use (both intracoronary and peripheral) over hours and the successful management of this complication after primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction.
No takes yet. Share an insight, caveat, or question.
Yurtdaş et al. (2014) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: